Market Cap | 4.12M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -1.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -65.00% |
Recommedations | - | Quick Ratio | 0.02 | Shares Outstanding | 147.17M | 52W Low Chg | 39.00% |
Insider Own | 11.61% | ROA | -459.53% | Shares Float | 130.72M | Beta | 0.68 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.03 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 53,551 | Target Price | - |
Oper. Margin | 780.83% | Earnings Date | May 30 | Volume | 5,085 | Change | 0.00% |
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. The comapny engages in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome. It has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.